PRDM9 and breast cancer: In the current study, we reported a novel regulatory network implicated in BC progression, which involves aberrant activation of the oncogenic histone methyltransferase EZH2 and miR-375 and the subsequent inhibition of FOXO1 and the p53 signaling pathway.